EDITORIAL
The antibody–drug conjugate era in gynaecological cancers
Recent approvals are driving a shift toward biomarker-informed treatment strategies, rational combinations and personalised sequencing
AI & DIGITAL ONCOLOGY
Multimodal AI biomarkers: from biology to patient stratification
Artificial intelligence is enabling a new class of biomarkers by integrating histology, molecular data, imaging, and clinical records to generate scalable, biologically grounded insights for precision oncology.
AI-driven multimodal strategy improves risk stratification in early breast cancer
Integrating digital pathology with genomic and clinical data may enhance prediction of late recurrence and refine selection for adjuvant treatment intensification in HR-positive, HER2-negative disease
Customised app shows promise for monitoring prostate cancer patients in real-time
A pilot study reports high levels of acceptance and compliance despite an older patient population
LATEST NEWS
Targeting the CD47-SIRPα axis continues to show promise in solid tumours
In early-phase studies, two novel agents showed low propensity to induce heamatological toxicities in heavily pre-treated solid tumours
Exploiting HER2 tumour heterogeneity with digital oncology
Multi-regional modelling reveals new ways to personalise treatments in gastric and breast cancers
First-line dual targeting combination shows encouraging, durable responses in triple-negative breast cancer
A manageable safety profile was also reported for pumitamig plus the antibody-drug conjugate DB-1305/BNT325 in an early-phase study
OPINIONS
ctDNA is unlocking new clinical opportunities for liquid biopsy
Kosei Hasegawa
Annual PSA screening in men with BRCA2 mutations at high genetic risk of prostate cancer
Heather H. Cheng
Optimal sequencing of immunotherapy in MSI-H/dMMR colon cancer remains uncertain
Dominik Modest
Can digital tools improve personalised support for adolescents and young adults with cancer?
Ivana Bozovic-Spasojevic
The management of invasive lobular breast cancer is evolving
Rinath Jeselsohn
OPINIONS
ctDNA is unlocking new clinical opportunities for liquid biopsy
Kosei Hasegawa
Annual PSA screening in men with BRCA2 mutations at high genetic risk of prostate cancer
Heather H. Cheng
Optimal sequencing of immunotherapy in MSI-H/dMMR colon cancer remains uncertain
Dominik Modest
Can digital tools improve personalised support for adolescents and young adults with cancer?
Ivana Bozovic-Spasojevic
The management of invasive lobular breast cancer is evolving
Rinath Jeselsohn